• Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant/Refractory Ovarian Cancer at ESMO Virtual Congress 2020

    8 days ago - By San Diego Biotechnology

    Treatment with olvimulogene nanivacirepvec -primed immunochemotherapy shows promising overall survival benefit in this heavily pretreated late-stage patient population- The majority of patients benefited from apparent reversal of platinum......
    Read more ...